Table 1.
Body mass index at baseline, kg per m2 | ||||
---|---|---|---|---|
<18.5 (N = 18) | 18.5–<25 (N = 271) | 25–<30 (N = 119) | ≥30 (N = 57) | |
BMI, kg per m2 | 18.0 (17.0–18.0) | 22.0 (21.0–23.0) | 27.0(25.0–28.0) | 32.5 (31.0–35.0) |
Age at baseline, years* | 29.6 (5.9) | 30.1 (7.4) | 31.6 (7.6) | 32.7 (7.4) |
Female, % | 91.3 | 71.9 | 62.8 | 69.5 |
Active smokera, % | 29.6 | 32.1 | 33.7 | 35.8 |
Country or region | 82.3 | 69.6 | 66.2 | 55.7 |
Central Europeb, % | ||||
Canada, % | 14.6 | 4.1 | 7.1 | 7.5 |
Scandinavia, % | 0.0 | 8.9 | 14.8 | 16.0 |
Southern Europe, % | 3.1 | 17.4 | 11.9 | 20.8 |
Time to CDMS, days | 415 (141–1,497) | 1,176 (351–1,804) | 1,064 (342–1,805) | 672 (136–1,806) |
Time to MDMSd, days | 191 (96.0–372.0) | 194 (100–700) | 214.0 (96.0–929.0) | 100 (86–558) |
INFß-1b treatment group, % | 62.1 | 62.6 | 68.1 | 51.0 |
Multifocal onset, % | 52.1 | 47.4 | 51.6 | ]29.0 |
T2 lesion number at screening | 33 (9.0–52.0) | 19.0 (7.0–40.0) | 17.0(8.0–33.0) | 13.0 (5.0–35.0) |
T2 lesion volume at screening, mm3 | 2,044 (1,107–8664) | 1,871 (621–4,790) | 1,947 (718–4,343) | 1,717 (389–2,987) |
Brain volume at screening, cm3 | 1,073 (1,056–1,097) | 1,056 (1,022–1,084) | 1,056 (1,019–1,082) | 1,048 (1,029–1070) |
EDSS at baseline | 1.5(1.0–2.0) | 1.5(1.0–2.0) | 1.5 (1.0–2.0) | 1.5(0.0–2.0) |
25(OH)D at baseline, nmol/L | 45.8 (38.5–61.3) | 47.0 (37.6–59.0) | 48.0 (37.7– 58.5) | 43.9 (34–51.6) |
Steroid use at baseline, % | 72.9 | 74.6 | 62.3 | 75.6 |
Values are medians (interquartile ranges) or percentages and are standardized to the age distribution of the study population.
Value is not age adjusted
Active smoker defined as having all cotinine measures—baseline, months 6, 12, and 24— >25 ng/mL
Central Europe: Belgium, Netherlands, Germany, Austria, Switzerland, Denmark, France, Great Britain, Hungary, Czech Republic, Poland, Slovenia; Southern Europe: Spain, Portugal, Italy, Israel; Scandinavia: Finland, Norway, Sweden
2001 McDonald MS